The first study on the Zika vaccine is already underway in the USA and Canada.
Some other technicals to consider would be the moving averages of the company. Further, we are pleased with the company's collaborations with other companies and institutes for pipeline development. These results showed an earnings surprise of 5.07% (Thomson Reuter's data). "Termination of the agreement with Roche for INO-1800 is also concerning".
A number of Wall Street analysts recently commented on the stock.
In order to reach an opinion/Recommendation the analyst research public financial statements, listen in on conference calls and talk to managers and the customers of a company, in attempt to capture the information for a research report. They set a "buy" rating and a $17.00 price objective for the company.
Many research firms have provided their ratings on Inovio Pharmaceuticals, Inc. In the past 52 weeks, the share price moved between $4.50 and $ 11.69. They now have a Dollars 18 price target on the stock. "Based on this investigation into the company's performance the analyst decides whether their stock is a "buy", sell" or hold.
4 analysts polled by Zacks Research now have a mean target price of $19.75 on Inovio Pharmaceuticals, Inc. (NASDAQ:INO) ended trading session higher at $8.27 with +1.47%. The Average Volume Traded by the company in the last trading session is at 1.18 Million. The stock's market capitalization is $602.45 million. The company's 50-day moving average price is $9.25 and its 200 day moving average price is $9.61. Inovio Pharmaceuticals has a one year low of $4.50 and a one year high of $11.69. The company posted actual EPS for the last quarter of $-0.26. The biopharmaceutical company reported ($0.26) EPS for the quarter, missing the Thomson Reuters' consensus estimate of ($0.21) by $0.05. Inovio Pharmaceuticals had a negative net margin of 88.19% and a negative return on equity of 22.29%. According to their predictions High & Low revenue estimates are 6 Million and 3.12 Million respectively. During the same period past year, the firm earned ($0.09) EPS.
Analysts on average are expecting revenue target $4.31M for next quarter (Quarter Ending Mar-17). They now have a United States dollars 9 price target on the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this hyperlink. BlackRock Group LTD increased its stake in Inovio Pharmaceuticals by 4.6% in the second quarter. ProShare Advisors LLC increased its stake in Inovio Pharmaceuticals by 0.5% in the second quarter. The company is expected to report its next EPS (earnings per share) on Nov 09 BMO. Bellevue Group AG purchased a new stake in Inovio Pharmaceuticals during the first quarter valued at about $2,308,000.
Brean Capital began new coverage on Inovio Pharmaceuticals, Inc. giving the company a "buy" rating. Finally, Swiss National Bank increased its stake in Inovio Pharmaceuticals by 2.2% in the second quarter. The stock gained a consensus recommendation of 1.4 on Zacks Investment Research where the scale runs from 1 to 5, 1 representing Strong buy and 5 showing Strong Sell. Institutional investors own 28.59% of the company's stock.
Inovio Pharmaceuticals, Inc (Inovio) is a bio-pharmaceutical company, which is involved in developing deoxyribonucleic acid (DNA) immunotherapies and vaccines focused on treating and preventing cancers and infectious diseases. The Company's DNA-based immunotherapies, in combination with its electroporation delivery devices, generates immune responses, in particular T cells, in the body to fight target diseases.